Form 4: United Therapeutics COO Exercises and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan on November 25, 2024.
Summary
- Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock on November 25, 2024.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
- The transactions involved multiple sales at varying prices, with weighted average prices reported for each set of trades.
- The shares were held in a trust where Mr. Benkowitz is a co-trustee and beneficiary, and another trust where his family members are beneficiaries.
- A total of 10,000 stock options were exercised and 10,000 shares were sold.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for insider transactions and does not indicate any positive or negative sentiment. It is a neutral event.
Industry Context
This is a routine filing for insider transactions and is common for executives who have stock options as part of their compensation. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any non-public information.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
- The reported transactions are similar to those of other executives who exercise stock options and sell shares for personal financial management.
- Companies like Amgen, Biogen, and Gilead Sciences also have executives who use 10b5-1 plans for stock transactions.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
- The transactions do not affect the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 08/07/2024 | Date the Rule 10b5-1 trading plan was established. |
| 11/25/2024 | Date of the stock option exercise and share sales. |
| 11/27/2024 | Date the Form 4 was signed. |
Keywords
stock options, Rule 10b5-1, insider trading, share sale, United Therapeutics, UTHR, Michael Benkowitz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.